Literature DB >> 20613900

The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women.

Seo Yeong Lee1, Mi Kyoung Kim, Hyun Park, Bo Sung Yoon, Seok Ju Seong, Jin Hee Kang, Hye Sun Jun, Chong Taik Park.   

Abstract

OBJECTIVE: Levonorgestrel releasing intrauterine system (LNG-IUS) has been shown to treat patients with non-atypical & atypical endometrial hyperplasia (EH) successfully in many western studies. Our purpose was to examine the effectiveness of LNG-IUS in the treatment of Korean women with EH.
METHODS: We conducted a prospective observational study of 12 women diagnosed with EH and treated with LNG-IUS insertion between February 2007 and August 2009 at the Department of Gynecology of Gangnam CHA Hospital, CHA University School of Medicine. Baseline endometrial biopsies were done before insertion of LNG-IUS, and outpatient follow-up endometrial biopsies were undertaken at 3-month intervals after insertion of LNG-IUS. We investigated the regression rate and the time to regression.
RESULTS: Four patients had simple hyperplasia without atypia, 7 patients complex hyperplasia without atypia, and just 1 patient complex atypical hyperplasia. Complete regression of EH was achieved in all cases (100%, 12/12), with the significant proportion (66%, 8/12) achieving it within 3 months. The mean duration to regression was 4.5 months. All cases had regression within 9 months. In the case of complex atypical hyperplasia, the regression was attained at the 9th month after insertion of LNG-IUS. The mean follow-up duration was 12 months (range, 3 to 27 months). As long as LNG-IUS was maintained, the EH did not recur.
CONCLUSION: LNG-IUS appears to be as highly effective in treating Korean women with EH.

Entities:  

Keywords:  Endometrial hyperplasia; Korean women; LNG-IUS; Mirena; Progestin

Year:  2010        PMID: 20613900      PMCID: PMC2895708          DOI: 10.3802/jgo.2010.21.2.102

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  14 in total

1.  Natural history of endometrial hyperplasia. Study of 77 patients.

Authors:  T Tabata; T Yamawaki; T Yabana; M Ida; K Nishimura; Y Nose
Journal:  Arch Gynecol Obstet       Date:  2001-05       Impact factor: 2.344

2.  The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group.

Authors:  N Terakawa; J Kigawa; Y Taketani; H Yoshikawa; A Yajima; K Noda; H Okada; J Kato; M Yakushiji; O Tanizawa; S Fujimoto; S Nozawa; T Takahashi; K Hasumi; N Furuhashi; T Aono; A Sakamoto; M Furusato
Journal:  J Obstet Gynaecol Res       Date:  1997-06       Impact factor: 1.730

3.  Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.

Authors:  Anne Beate Vereide; Turid Kaino; Georg Sager; Marit Arnes; Anne Ørbo
Journal:  Gynecol Oncol       Date:  2005-12-01       Impact factor: 5.482

4.  Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.

Authors:  Anne Ørbo; Marit Arnes; Christine Hancke; Anne Beate Vereide; Inger Pettersen; Kurt Larsen
Journal:  Gynecol Oncol       Date:  2008-08-06       Impact factor: 5.482

5.  Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up.

Authors:  D Wildemeersch; D Janssens; K Pylyser; N De Wever; G Verbeeck; M Dhont; W Tjalma
Journal:  Maturitas       Date:  2007-01-31       Impact factor: 4.342

6.  The management of endometrial hyperplasia: an evaluation of current practice.

Authors:  T Justin Clark; Deepa Neelakantan; Janesh K Gupta
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-10-24       Impact factor: 2.435

7.  Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone.

Authors:  A B Vereide; M Arnes; B Straume; J M Maltau; A Ørbo
Journal:  Gynecol Oncol       Date:  2003-12       Impact factor: 5.482

8.  The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients.

Authors:  R J Kurman; P F Kaminski; H J Norris
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

9.  The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.

Authors:  Rajesh Varma; Hemi Soneja; Kalsang Bhatia; Raji Ganesan; Terence Rollason; T Justin Clark; Janesh K Gupta
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2008-04-28       Impact factor: 2.435

Review 10.  Endometrial hyperplasia: a review.

Authors:  Ben E Montgomery; Gary S Daum; Charles J Dunton
Journal:  Obstet Gynecol Surv       Date:  2004-05       Impact factor: 2.347

View more
  9 in total

Review 1.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

Review 2.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

3.  LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial.

Authors:  Hatem Abu Hashim; Abdelhady Zayed; Essam Ghayaty; Mohamed El Rakhawy
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

4.  LNG-IUS treatment of non-atypical endometrial hyperplasia: Can Pipelle endometrial sampling be an accurate method of follow-up evaluation?

Authors:  Mi Kyoung Kim; Seok Ju Seong
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

5.  Oral and intrauterine progestogens for atypical endometrial hyperplasia.

Authors:  Li Luo; Bing Luo; Ying Zheng; Heng Zhang; Jing Li; Neil Sidell
Journal:  Cochrane Database Syst Rev       Date:  2018-12-04

6.  Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method?

Authors:  Mi Kyoung Kim; Seok Ju Seong
Journal:  J Gynecol Oncol       Date:  2014-07       Impact factor: 4.401

Review 7.  Clinical Use of Progestins and Their Mechanisms of Action: Present and Future (Review).

Authors:  T A Fedotcheva
Journal:  Sovrem Tekhnologii Med       Date:  2021-02-28

8.  Coexisting carcinoma in endometrial hyperplasia: does more risk factor mean better discrimination?

Authors:  Sokbom Kang
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

9.  Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study.

Authors:  Mi Kyoung Kim; Seok Ju Seong; Dong Choon Park; Jin Hwa Hong; Ju Won Roh; Soon Beom Kang
Journal:  J Gynecol Oncol       Date:  2020-02-07       Impact factor: 4.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.